NEUMORA THERAPEUTICS, INC. Pre-Tax Income
NEUMORA THERAPEUTICS, INC. (NMRA) reported Pre-Tax Income of -$43.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$43.08M.
- NEUMORA THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$53.43M.
- NEUMORA THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$59.45M.
- NEUMORA THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$56.76M.
- NEUMORA THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$236.80M.
- NEUMORA THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$243.61M.
- NEUMORA THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$235.66M.
- NEUMORA THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$130.90M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$43.08M 10-Q · filed 2026-08-14 | -$96.51M 10-Q · filed 2026-08-14 | -$155.96M derived: sum of 3 quarters · filed 2026-08-14 | -$212.72M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$53.43M 10-Q · filed 2026-05-07 | -$112.88M derived: sum of 2 quarters · filed 2026-05-07 | -$169.63M derived: sum of 3 quarters · filed 2026-05-07 | -$222.34M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$59.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$116.20M derived: sum of 2 quarters · filed 2026-03-30 | -$168.91M derived: sum of 3 quarters · filed 2026-08-14 | -$236.80M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$56.76M 10-Q · filed 2025-11-06 | -$109.46M derived: sum of 2 quarters · filed 2026-08-14 | -$177.35M 10-Q · filed 2025-11-06 | -$236.17M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$52.71M 10-Q · filed 2026-08-14 | -$120.59M 10-Q · filed 2026-08-14 | -$179.41M derived: sum of 3 quarters · filed 2026-08-14 | -$251.91M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$67.89M 10-Q · filed 2026-05-07 | -$126.71M derived: sum of 2 quarters · filed 2026-05-07 | -$199.20M derived: sum of 3 quarters · filed 2026-05-07 | -$257.77M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$58.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$131.31M derived: sum of 2 quarters · filed 2026-03-30 | -$189.89M derived: sum of 3 quarters · filed 2026-03-30 | -$243.61M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$72.49M 10-Q · filed 2025-11-06 | -$131.07M derived: sum of 2 quarters · filed 2025-11-06 | -$184.79M 10-Q · filed 2025-11-06 | -$293.25M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$58.58M 10-Q · filed 2025-08-06 | -$112.30M 10-Q · filed 2025-08-06 | -$220.76M derived: sum of 3 quarters · filed 2025-08-06 | -$273.79M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$53.72M 10-Q · filed 2025-05-12 | -$162.18M derived: sum of 2 quarters · filed 2025-05-12 | -$215.21M derived: sum of 3 quarters · filed 2025-05-12 | -$253.75M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$108.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$161.49M derived: sum of 2 quarters · filed 2025-03-03 | -$200.03M derived: sum of 3 quarters · filed 2025-03-03 | -$235.66M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$53.03M 10-Q · filed 2024-11-12 | -$91.57M derived: sum of 2 quarters · filed 2024-11-12 | -$127.19M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$38.54M 10-Q · filed 2024-08-06 | -$74.17M 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | -$130.90M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |